IMAX CHINA(01970.HK)中期收入4390萬美元 同比減少3.1%
格隆匯7月25日丨IMAX CHINA(01970.HK)公吿,截至2024年6月30日止6個月的中期業績,集團的收入由2023年財政年度上半年的4530萬美元減至2024年財政年度上半年的4390萬美元,減幅為3.1%,是由於內容解決方案收入減少490萬美元,部分被技術產品及服務收入增加3.2百萬美元以及所有其他收入增加0.2百萬美元所抵銷,下文將作出進一步解釋。2024年財政年度上半年,集團錄得期內利潤1260萬美元,而2023年財政年度上半年錄得利潤1390萬美元。公司擁有人應占每股利潤0.04美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.